CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [RNA-seq]
RNA-seq (gene expression) · human · 30 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 30 samples: 7 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE300974_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1282760 and SRA study SRP594941. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 20 samples.
How we read this: 7 replicated groups read from 30 sample titles; they account for 20 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9072897 RNAseq_Rh30_DMSO_D1_rep1 RNAseq_Rh30_DMSO_D1
- GSM9072898 RNAseq_Rh30_DMSO_D1_rep2 RNAseq_Rh30_DMSO_D1
- GSM9072899 RNAseq_Rh30_DMSO_D1_rep3 RNAseq_Rh30_DMSO_D1
- GSM9072900 RNAseq_Rh30_DMSO_D3_rep1 RNAseq_Rh30_DMSO_D3
- GSM9072901 RNAseq_Rh30_DMSO_D3_rep2 RNAseq_Rh30_DMSO_D3
- GSM9072902 RNAseq_Rh30_DMSO_D7_rep1 RNAseq_Rh30_DMSO_D7
- GSM9072903 RNAseq_Rh30_DMSO_D7_rep2 RNAseq_Rh30_DMSO_D7
- GSM9072904 RNAseq_Rh30_DMSO_D7_rep3 RNAseq_Rh30_DMSO_D7
- GSM9072905 RNAseq_Rh30_BI1347_D1_rep1 RNAseq_Rh30_BI1347_D1
- GSM9072906 RNAseq_Rh30_BI1347_D1_rep2 RNAseq_Rh30_BI1347_D1
- GSM9072907 RNAseq_Rh30_BI1347_D1_rep3 RNAseq_Rh30_BI1347_D1
- GSM9072908 RNAseq_Rh30_BI1347_D3_rep1
- GSM9072909 RNAseq_Rh30_Bi1347_D3_rep3
- GSM9072910 RNAseq_Rh30_BI1347_D7_rep1 RNAseq_Rh30_BI1347_D7
- GSM9072911 RNAseq_Rh30_BI1347_D7_rep2 RNAseq_Rh30_BI1347_D7
- GSM9072912 RNAseq_Rh30_BI1347_D7_rep3 RNAseq_Rh30_BI1347_D7
- GSM9072913 RNAseq_Rh30_sgChr2.2_rep1 RNAseq_Rh30_sgChr2.2
- GSM9072914 RNAseq_Rh30_sgChr2.2_rep2 RNAseq_Rh30_sgChr2.2
- GSM9072915 RNAseq_Rh30_sgChr2.2_rep3 RNAseq_Rh30_sgChr2.2
- GSM9072916 RNAseq_Rh30_sgCDK8-3_rep1 RNAseq_Rh30_sgCDK8-3
- GSM9072917 RNAseq_Rh30_sgCDK8-3_rep2 RNAseq_Rh30_sgCDK8-3
- GSM9072918 RNAseq_Rh30_sgCDK8-3_rep3 RNAseq_Rh30_sgCDK8-3
- GSM9072919 RNAseq_Rh30_DMSO_repeat_A
- GSM9072920 RNAseq_Rh30_DMSO_repeat_B
- GSM9072921 RNAseq_Rh30_BI1347_D1_repeat_A
- GSM9072922 RNAseq_Rh30_BI1347_D1_repeat_B
- GSM9072923 RNAseq_Rh30_BI1347_D3_repeat_A
- GSM9072924 RNAseq_Rh30_Bi1347_D3_repeat_B
- GSM9072925 RNAseq_Rh30_BI1347_D7_repeat_A
- GSM9072926 RNAseq_Rh30_BI1347_D7_repeat_B
- GSE303028 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma 104 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade, alveolar
- GSE303151 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [CUT&RUN] 50 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade, alveolar
- GSE329566 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [ChIP-Seq] 8 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade, alveolar
- GSE303149 CDK8 Inhibition Releases the Muscle Differentiation Blockade in Fusion-driven Alveolar Rhabdomyosarcoma [ATAC-seq] 6 samples same disease briefing · shares cdk8, rhabdomyosarcoma, fusion-driven, inhibition, releases, blockade, alveolar
- GSE312030 Combined inhibition of HRAS and MEK induces tumor regression and restores myogenic differentiation in HRAS-mutant rhabdomyosarcoma 159 samples same disease briefing · shares rhabdomyosarcoma, inhibition
- GSE292872 FANCM is Required for the PAX3::FOXO1-Driven Oncogenic Program in Rhabdomyosarcoma [RNA-Seq] 21 samples same disease briefing · shares rhabdomyosarcoma, rna-seq
- GSE240287 RNA-sequencing of matched samples from rhabdomyosarcoma samples, obtained before therapy and mid-treatment resection 18 samples same disease briefing · shares rhabdomyosarcoma, rna-seq
- GSE313525 TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma 6 samples same disease briefing · shares rhabdomyosarcoma, blockade
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.